Evotec Wins Vertex Manufacturing Mandate as RBC Holds Its Ground on a Halved Target

Evotec has been picked by Vertex Pharmaceuticals to handle commercial manufacturing of povetacicept, a contract that gives the German drug developer a tangible foothold in future business at its Just – Evotec Biologics unit. The award landed alongside RBC Capital Markets' decision to keep its Outperform rating and 5 € price target on the stock, a stance the bank reaffirmed after the final quarterly figures matched the preliminary numbers it had already seen.

The shares climbed 6.0% on the day. That move is no verdict on the turnaround itself — judging the recovery means separating savings already banked from the restructuring still to come, and that gap is where the next few months will be decided.

A target cut that predates the confirmation

RBC's 5 € objective is not new. The bank trimmed it from 10 € on 30 October, citing an adjustment to its valuation model ahead of the final nine-month numbers, while leaving the Outperform rating and its "Speculative Risk" tag in place. Analyst Charles Weston's subsequent confirmation of the positive stance therefore signals no fresh earnings surprise — it shows the house is standing by its valuation.

The distinction matters. A positive relative call can coexist with a sharply lower price target and an explicitly speculative risk label. The unchanged rating should not obscure the reduced benchmark, and the lower target does not turn the call negative either. Reading only the label misses the caveat.

Should investors sell immediately? Or is it worth buying Evotec?

Horizon: measurable progress, unfinished work

The Horizon programme is meant to shave 75 Mio. € from the annual cost base by the end of 2027. By the end of September, more than 20% of the planned improvement had been achieved — a quantifiable milestone, not the finish line.

Up to 800 jobs are slated for removal and four sites for closure. Roughly half of the personnel measures have been carried out, leaving a substantial share of the staffing changes still ahead. Three closures are scheduled by the end of 2026, with the fourth to follow in the first quarter of 2027.

What investors ultimately need is a lower cost base that holds, making Evotec less vulnerable to swinging revenues. Headcount cuts and site shutdowns are means to that end, not standalone proof of success. The most persuasive outcome would pair further savings with steadier operating performance.

The top line is still moving the wrong way

Against the cost story sits a harder fact: group revenue fell 13.1% to 465,0 Mio. € in the first nine months of 2026. Adjusted earnings remained negative, with the preliminary figure for adjusted group EBITDA at around -42,8 Mio. €.

Both revenue and EBITDA came in above market expectations, according to the company, and the full-year guidance was confirmed. That is operating relief, not a contradiction of the cautious valuation — beating expectations while still in the red is not the same as being profitable.

There are pockets of growth. Net sales in the D&PD base business rose 24% year on year over the same nine-month stretch, a positive signal within a weaker group picture. Partnerships with Odyssey and Plectonic, together with the Vertex manufacturing contract, show Evotec kept signing commercial agreements during the overhaul. What those deals will contribute to earnings cannot yet be derived from them.

Management is targeting an adjusted EBITDA margin of 20% by the end of 2028. That is an objective, not a secured trajectory; further savings would have to show up in the results while the business supplies enough support.

Three signals, three different questions

A regulatory filing adds a third data point that should not be folded into the other two. JPMorgan Chase & Co.'s mandatory disclosure, published a day before the results, showed its total share of voting rights and financial instruments slipping to 6,11% as of 30 October from 6,54% previously.

Evotec at a turning point? This analysis reveals what investors need to know now.

The filing explicitly covers both voting rights from shares and financial instruments, so it is not equivalent to a change in a pure equity stake — and it offers no rationale for the positioning. A mandatory disclosure describes a holding; an analyst study expresses a valuation judgment; company figures show economic development. These can sit side by side without telling the same story, and collapsing them into a single sentiment gauge would be too easy.

What the next checkpoint has to prove

The bear case is a persistently weak revenue trend combined with a stalling Horizon rollout. In that scenario investors could rely neither on dependable operating relief nor on sufficient growth, and the confirmed positive analyst view would not dispel the uncertainty.

The bull case rests on a combination: a falling cost base meeting a better business trajectory. If both arrive, Evotec could stabilise its earnings position and the investment case would no longer hinge solely on further cuts.

For now, the site plans set the timetable. Whether they produce lasting relief — rather than the next positive share-price reaction — remains the yardstick by which Evotec's recovery will be measured.

Ad

Evotec Stock: New Analysis - 5 November

Fresh Evotec information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Evotec analysis...